Brokerages Set Certara, Inc. (NASDAQ:CERT) Price Target at $11.10

Certara, Inc. (NASDAQ:CERT) has earned an average rating of “Hold” from the fourteen brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.10.

CERT has been the topic of several recent research reports. Morgan Stanley lowered their price target on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. Wall Street Zen cut shares of Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. KeyCorp decreased their target price on shares of Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, January 8th. TD Cowen reissued a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th.

Hedge Funds Weigh In On Certara

Large investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. raised its holdings in Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after buying an additional 2,870 shares during the period. First Horizon Corp purchased a new position in Certara during the third quarter worth about $30,000. Versant Capital Management Inc increased its position in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after acquiring an additional 1,153 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the last quarter. Finally, Global Retirement Partners LLC raised its stake in shares of Certara by 45.0% in the 3rd quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock valued at $69,000 after acquiring an additional 1,749 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Price Performance

NASDAQ:CERT opened at $5.41 on Friday. Certara has a one year low of $5.24 and a one year high of $15.38. The stock has a market cap of $860.95 million, a PE ratio of -541.00 and a beta of 1.62. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05. The stock has a 50 day moving average price of $6.93 and a 200 day moving average price of $9.08.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The company had revenue of $103.65 million for the quarter, compared to analyst estimates of $103.23 million. During the same period last year, the firm posted $0.15 EPS. The business’s quarterly revenue was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Equities research analysts expect that Certara will post 0.28 EPS for the current fiscal year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.